Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

Author(s): Aragon-Ching JB,  Ning YM,  Chen CC,  Latham L,  Guadagnini JP,  Gulley JL,  Arlen PM,  Wright JJ,  Parnes H,  Figg WD,  Dahut WL

Journal: Cancer Invest

Date: 2009 Feb

Major Program(s) or Research Group(s): PUCRG

PubMed ID: 19235596

PMC ID: PMC2648132

Abstract: ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.